{
  "ticker": "AGN",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960381",
  "id": "02960381",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250620",
  "time": "0954",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250620/pdf/06ky3jn2zbr300.pdf",
  "summary": "**Key Points from ASX Announcement:**  \n\n- **Non-dilutive funding of up to $1.5M** awarded under the MRFF Targeted Translation Research Accelerator program.  \n- **First tranche ($1M) secured**, with an additional **$500K contingent** on progress/commercial potential.  \n- **Funds to support Phase 2b/3 clinical trial** for ARG-007 in acute ischaemic stroke.  \n- **Trial data from completed Phase 2 expected Q3 2025**.  \n- **Full IP and commercialization rights retained** by Argenica.  \n- **Funding agreement finalization targeted by 30 June 2025**.",
  "usage": {
    "prompt_tokens": 988,
    "completion_tokens": 143,
    "total_tokens": 1131,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-19T23:59:14.855457"
}